Loading...
•
Dec 31, 2020
Arvinas Q4 2020 Earnings Report
Arvinas reported financial results and provided a corporate update.
Key Takeaways
Arvinas reported positive efficacy signals in both clinical-stage programs and closed an underwritten public offering of common stock, receiving net proceeds of $431.9 million. The company's cash, cash equivalents, and marketable securities are expected to fund operations into 2024.
Presented interim Phase 1 data for ARV-471 showing potential for best-in-class safety and tolerability and a robust efficacy signal in heavily pretreated patients with ER+/HER2- breast cancer.
Presented data from the ongoing dose escalation portion of the Phase 1/2 trial of ARV-110 in men with mCRPC, providing additional evidence of anti-tumor activity and patient benefit.
Closed an underwritten public offering of 6,571,428 shares of common stock at a public offering price of $70.00 per share, receiving net proceeds of $431.9 million.
Initiated the ARDENT Phase 2 dose expansion study of ARV-110 and the VERITAC Phase 2 dose expansion study of ARV-471.
Forward Guidance
Arvinas expects its cash, cash equivalents, and marketable securities will be sufficient to fund its planned operating expenses and capital expenditures into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...